Pradaxa (dabigatran etexilate) is a blood thinner that has been linked with an increased risk of internal bleeding and hemorrhaging. Known also as dabigatran etexilate and sold by Boehringer Ingelheim, it is prescribed to help reduce the risk of stroke due to atrial fibrillation.
If you or someone you know has suffered due to taking this drug and suffering from a bleeding or hemorrhaging disorder, the New York drug liability attorneys at Rheingold Giuffra Ruffo & Plotkin LLP can help you explore your options for legal recourse.
Serving Clients Across the Country
Call (888) 260-0473 to speak with a legal team boasting more than 30 years of experience litigating dangerous drug cases.
Pradaxa and Internal Bleeding
Use of Pradaxa was first associated with uncontrolled bleeding while being used in elderly patients in New Zealand. This news was in September, 2011, at which time it was further discovered that the bleeding was uncontrollable. With other drugs, such as warfarin, bleeding was easy to stem by using vitamin K. However, this is not so with Pradaxa, and this defect could result in life-threatening consequences. Similar reports occurred in Japan, and the Cleveland Clinic also confirmed these problems in early 2012.
Lawsuits & financial recovery
Medical treatment for these side effects can be expensive. The people responsible for releasing this drug without properly warning of the consequences should be held accountable for your pain and suffering and financial burden. Our New York drug liability attorneys aggressively litigate cases to ensure our clients receive all the compensation they are owed.